Changes in the gene expression of activation-induced cytidine deaminase in peripheral blood mononuclear cells in COVID-19 patients

Abstract

Objective: To assess the changes in gene expression of activation-induced cytidine deaminase ( AID) in COVID-19 patients and its relationship with the presence of autoantibodies in those ones. Methods: This retrospective study was carried out among COVID-19 patients’ serum and peripheral blood mononuclear cells that were archived at the main COVID-19 referral centers in Iran from January to March 2022. The titer of autoantibodies in the serum of healthy and COVID-19 subjects was investigated by serological tests. Then, the AID gene expression in peripheral blood mononuclear cells in two groups was evaluated using the real-time polymerase chain reaction method. Results: 100 patients were included. In total, 8% and 1% of patients had a significant titer of anti-citrullinated protein antibody and antinuclear antibody autoantibodies, respectively, and those suffered from at least one comorbidity. No patient was positive for antiphospholipid autoantibody. Moreover, no significant changes were observed in the titer of autoantibodies between healthy subjects and patients. Furthermore, the increase in the expression of the AID gene was not significant in two groups. Conclusions: The presence of autoantibodies in COVID-19 patients might be linked to the previous underlying disease.

Keywords

SARS-CoV-2 / Activation-induced cytidine deaminase / Anti-nuclear antibody / Anti-phospholipid antibody / Anti-cyclic citrullinated peptide antibody

References

[1] Nasr Esfahani BN, Ahadi AM, Shalibeik S. A review of novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS—CoV—2). Iran J Med Microbiol 2020; 14(2): 154-161.

[2] Nikolich—Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS—CoV—2 and COVID—19 in older adults: What we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience 2020; 42(2): 505-514.

[3] Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID—19. Nat Rev Rheumatol 2020; 16(8): 413-414.

[4] Zhou Y, Han T, Chen J, Hou C, Hua L, He S, et al. Clinical and autoimmune characteristics of severe and critical cases of COVID—19. Clin Transl Sci 2020; 13(6): 1077-1086.

[5] Toussirot É, Roudier J. Epstein—Barr virus in autoimmune diseases. Best Pract Res Clin Rheumatol 2008; 22(5): 883-896.

[6] Halenius A, Hengel H. Human cytomegalovirus and autoimmune disease. Biomed Res Int 2014; 2014: 472978.

[7] Zandman—Goddard G, Shoenfeld Y. HIV and autoimmunity. Autoimmun Rev 2002; 1(6): 329-337.

[8] Quaresma JAS, Yoshikawa GT, Koyama RVL, Dias GAS, Fujihara S, Fuzii HT. HTLV—1, immune response and autoimmunity. Viruses 2015; 8(1): 5.

[9] Ruscitti P, Berardicurti O, Iagnocco A, Giacomelli R. Cytokine storm syndrome in severe COVID—19. Autoimmun Rev 2020; 19(7): 102562.

[10] Kalfaoglu B, Almeida—Santos J, Tye CA, Satou Y, Ono M. T—cell hyperactivation and paralysis in severe COVID—19 infection revealed by single—cell analysis. Front Immunol 2020; 8(11): 589380.

[11] Gao Z, Zhang H, Liu C, Dong KE. Autoantibodies in COVID—19: Frequency and function. Autoimmun Rev 2021; 20(3): 102754.

[12] Dobrowolska K, Zarębska—Michaluk D, Poniedziałek B, Jaroszewicz J, Flisiak R, Rzymski P. Overview of autoantibodies in COVID—19 convalescents. J Med Virol 2023; 95(6): e28864.

[13] Baiocchi GC, Vojdani A, Rosenberg AZ, Vojdani E, Halpert G, Ostrinski Y, et al. Cross—sectional analysis reveals autoantibody signatures associated with COVID—19 severity. J Med Virol 2023; 95(2): e28538.

[14] Son K, Jamil R, Chowdhury A, Mukherjee M, Venegas C, Miyasaki K, et al. Circulating anti—nuclear autoantibodies in COVID—19 survivors predict long COVID symptoms. Eur Respir J 2023; 61(1): 2200970.

[15] Chang R, Chen TYT, Wang SI, Hung YM, Chen HY, Wei CCJ. Risk of autoimmune diseases in patients with COVID—19: A retrospective cohort study. EClinicalMedicine 2023; 56: 101783.

[16] Al—Beltagi M, Saeed NK, Bediwy AS. COVID—19 disease and autoimmune disorders: A mutual pathway. World J Methodol 2022; 12(4): 200.

[17] Kumar R, DiMenna L, Chaudhuri J, Evans T. Biological function of activation—induced cytidine deaminase ( AID) . Biomed J 2014; 37(5): 269-283.

[18] Hase K, Takahashi D, Ebisawa M, Kawano S, Itoh K, Ohno H. Activation—induced cytidine deaminase deficiency causes organ—specific autoimmune disease. PLoS One 2008; 3(8): e3033.

[19] Durandy A, Cantaert T, Kracker S, Meffre E. Potential roles of activation—induced cytidine deaminase in promotion or prevention of autoimmunity in humans. Autoimmunity 2013; 46(2): 148-156.

[20] Hsu HC, Wu Y, Yang P, Wu Q, Job G, Chen J, et al. Overexpression of activation—induced cytidine deaminase in B cells is associated with production of highly pathogenic autoantibodies. J Immunol 2007; 178(8): 5357-5365.

[21] Endo Y, Marusawa H, Kou T, Nakase H, Fujii S, Fujimori T, et al. Activation—induced cytidine deaminase links between inflammation and the development of colitis—associated colorectal cancers. Gastroenterology 2008; 135(3): 889-898.

[22] Noguchi E, Shibasaki M, Inudou M, Kamioka M, Yokouchi Y, Yamakawa—Kobayashi K, et al. Association between a new polymorphism in the activation—induced cytidine deaminase gene and atopic asthma and the regulation of total serum IgE levels. J Allergy Clin Immunol 2001; 108(3): 382-386.

[23] Russi S, Dammacco F, Sansonno S, Pavone F, Sansonno D. Activation—induced cytidine deaminase in B cells of hepatits C virus—related cryoglobulinaemic vasculitis. Clin Exp Immunol 2015; 182(3): 323-331.

[24] Epeldegui M, Breen EC, Hung YP, Boscardin WJ, Detels R, Martínez—Maza O. Elevated expression of activation induced cytidine deaminase in peripheral blood mononuclear cells precedes AIDS—NHL diagnosis. AIDS 2007; 21(17): 2265-2270.

[25] Nagata K, Kumata K, Nakayama Y, Satoh Y, Sugihara H, Hara S, et al. Epstein—Barr virus lytic reactivation activates B cells polyclonally and induces activation—induced cytidine deaminase expression: A mechanism underlying autoimmunity and its contribution to Graves’ disease. Viral Immunol 2017; 30(3): 240-249.

[26] Gilanipour A, Teimoori A, Arabzadeh SA, Mollaie HR, Mousavi E. Toll—like receptor 7 and RIG—I—like receptors expression in peripheral blood mononuclear cells of naïve patients with hepatitis C. BMC Res Notes 2023; 16(1): 344.

[27] Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID—19). J Transl Autoimmun 2020; 3: 100073.

[28] Zuo Y, Estes SK, Ali RA, Gandhi AA, Yalavarthi S, Shi H, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID—19. Sci Transl Med 2020; 12(570): eabd3876.

[29] Marin GG, Cardiel MH, Cornejo H, Viveros ME. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol 2009; 15(7): 325-329.

[30] Tipu HN. Frequency of antinuclear autoantibodies among healthy volunteers. Pakistan Armed Forces Med J 2011; 61(4): 534-536.

[31] Tan EM, Feltkamp TEW, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum 1997; 40(9): 1601-1611.

[32] Stjepanovic MI, Stojanovic MR, Stankovic S, Cvejic J, Dimic—Janjic S, Popevic S, et al. Autoimmune and immunoserological markers of COVID—19 pneumonia: Can they help in the assessment of disease severity. Front Med 2022; 29(9): 934270.